Compare ADMA Biologics Inc (ADMA) vs Qurate Retail Inc Series A (QVCAQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Qurate Retail Inc Series A — how do they compare? ADMA Biologics Inc trades at $9.24 (market cap $2.13B), while Qurate Retail Inc Series A trades at $0.08 (market cap $1.12M). The key difference: ADMA Biologics Inc is far larger — about 1901.8× Qurate Retail Inc Series A's market cap, and ADMA Biologics Inc is trading nearer its 52-week high, Qurate Retail Inc Series A nearer its low. Which is the better fit depends on your goals.
| ADMA | QVCAQ | |
|---|---|---|
Market Cap | $2.13B | $1.12M |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $15.03 |
52-Week Low | $7.60 | $0.07 |
Enterprise Value | $2.20B | $4.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
QVCAQ trades at $0.109, up 37.97% in 24 hours, but technical signals are bearish with 13 sell signals on moving averages. The company reported a net loss of $2.44 billion in 2025, with negative shareholder equity of $971 million and a debt-to-asset ratio of 77.57%. Recent news highlights QVC's 40th anniversary and TikTok Shop partnership (PRNewsWire, 2026-05-28).
The outlook remains highly speculative due to persistent losses, negative equity, and high leverage. Risks include financial distress and competitive pressures, while any positive sentiment hinges on operational turnarounds. Investors should approach with caution given the fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Qurate Retail Inc Series A
Qurate Retail Inc, through its subsidiaries, is engaged in the video and online commerce industries. Its segments include QxH, which includes QVC U.S. and HSN market and sell a wide variety of consumer products in the United States, primarily using their televised shopping programs and via the Internet through their websites and mobile applications
Read more on QVCAQ →
